WEE1 and prostate cancer: Regarding the proportion of the mutations in prostate cancer patients, 10% (10/100) of patients carried variants in DNA methylation pathway, 6% in DDR, 6% in tyrosine-protein kinase pathway, 4% in GPCR signaling and 4% in peroxisome pathway (Fig 4B).